VPA10987/161/001

Clindacyl 300 mg Tablets for Dogs

Variation	Summary	Date
Vet - B44 a)	VNRA - Vet - B44 a) - - Vet - B44 a) - Submission of a Ph. Eur. CEP for:— active substance;— starting material, reagent or intermediate used in the manufacturing process of the active substance;— excipient - Updated cerificate	29/01/26
Vet - B43	VNRA - Vet - B43 - - Vet - B43 - Editorial changes to part 2 of the dossier if inclusion in an upcoming procedure concerning part 2 is not possible	23/09/25
Vet - B28 a)	VNRA - Vet - B28 a) - - Vet - B28 a) - Change in the specification parameters or limits of an excipient tightening of specification limits	23/09/25
Vet - C8	VNRA - Vet - C8 - Implementation of changes in the SPC not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C8 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Implementation of changes in the SPC not already covered elsewhere in the Annex to Regulation (EU) 2021/17	14/05/24
Vet - G.I.18	VRA-S - Vet - G.I.18 - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004 - G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	01/03/24